Verastem Oncology, led by Ras, began using LinkedIn on August 27, 2025, to share updates about its medicines targeting RAS/MAPK pathway-driven cancers.
3 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Verastem Oncology, led by Ras, began using LinkedIn on August 27, 2025, to share updates about its medicines targeting RAS/MAPK pathway-driven cancers.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Verastem Oncology uses LinkedIn to announce its focus on RAS/MAPK pathway cancers.1 source
Verastem Oncology followed a company on LinkedIn in July 2025.1 source
Keep exploring
The entities involved
-
Verastem Oncology
Pharmaceutical company in Masachussets, United States
Nothing else this week.
-
LinkedIn
American social networking website for people in professional occupations
Related events
Coverage
Newest first; wire copies grouped- Business WireVerastem Oncology to Present at Upcoming Investor Conferences BOSTON, August 27, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medici
- Insider MonkeyVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects Verastem, Inc. (NASDAQ:VSTM) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company progresses with its
- Business WireVerastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 BOSTON, July 29, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to